Anifrolumab

Phase 2Active

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Hidradenitis Suppurativa

Conditions

Hidradenitis Suppurativa, Acne Inversa, Hidradenitis

Trial Timeline

Jun 21, 2024 → Apr 1, 2026

NCT ID

NCT06374212

About Anifrolumab

Anifrolumab is a phase 2 stage product being developed by AstraZeneca for Hidradenitis Suppurativa. The current trial status is active. This product is registered under clinical trial identifier NCT06374212. Target conditions include Hidradenitis Suppurativa, Acne Inversa, Hidradenitis.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (13)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04750057	Pre-clinical	Completed	—	—	Systemic Lupus Erythematosus
NCT07431775	Pre-clinical	Recruiting	Oct 1, 2026	Mar 31, 2032	Systemic Lupus Erythematosus
NCT07430306	Phase 3	Recruiting	Apr 1, 2026	Jan 26, 2029	Systemic Lupus Erythematosus
NCT07000110	Pre-clinical	Recruiting	Jan 26, 2026	Nov 30, 2031	Systemic Lupus Erythematosus
NCT06594068	Approved	Recruiting	Jan 16, 2026	Aug 31, 2027	Systemic Lupus Erythematosus
NCT07330245	Pre-clinical	Recruiting	Dec 31, 2025	Sep 30, 2028	Lupus Erythematosus, Systemic
NCT06795893	Pre-clinical	Recruiting	Nov 7, 2025	Apr 15, 2031	Systemic Lupus Erythematosus
NCT06659029	Pre-clinical	Recruiting	Jul 1, 2025	Apr 15, 2031	Systemic Lupus Erythematosus
NCT06673043	Pre-clinical	Recruiting	Feb 28, 2025	Jun 30, 2028	Lupus Erythematosus, Systemic
NCT06662123	Phase 1	Completed	Oct 21, 2024	Jan 10, 2025	Healthy Volunteers
NCT06374212	Phase 2	Active	Jun 21, 2024	Apr 1, 2026	Hidradenitis Suppurativa
NCT05339100	Phase 1	Completed	Mar 22, 2022	Apr 13, 2023	Healthy Participants Study
NCT05001698	Phase 1	Completed	Jul 27, 2021	Jun 2, 2022	Systemic Lupus Erythematosus

Competing Products

20 competing products in Hidradenitis Suppurativa

See all competitors

Product	Company	Stage	Hype Score
Sonelokimab	MoonLake Immunotherapeutics	Phase 3	72
Sonelokimab	MoonLake Immunotherapeutics	Phase 3	72
Sonelokimab + Placebo	MoonLake Immunotherapeutics	Phase 3	72
Sonelokimab + Placebo	MoonLake Immunotherapeutics	Phase 3	72
Sonelokimab (M1095) + Adalimumab	MoonLake Immunotherapeutics	Phase 2	47
Eltrekibart + Placebo	Eli Lilly	Phase 2	52
Placebo + LY3041658	Eli Lilly	Phase 2	52
Placebo + Adalimumab	AbbVie	Approved	85
Lutikizumab + Placebo	AbbVie	Phase 3	77
Adalimumab	AbbVie	Pre-clinical	23
Upadacitinib + Placebo	AbbVie	Phase 3	77
adalimumab + placebo	AbbVie	Phase 3	77
Lutikizumab	AbbVie	Phase 2	52
adalimumab	AbbVie	Phase 3	77
Lutikizumab + Placebo	AbbVie	Phase 2	52
Risankizumab + Placebo for risankizumab	AbbVie	Phase 2	52
adalimumab	AbbVie	Phase 3	77
adalimumab + placebo	AbbVie	Phase 3	77
Upadacitinib + Placebo	AbbVie	Phase 2	52
MEDI8968 + Saline	AstraZeneca	Phase 2	52

Other Products from AstraZeneca

QuetiapineApproved

Dapagliflozin 5 mg + Placebo tabletApproved

QuetiapineApproved

Ticagrelor + ClopidogrelApproved

DurvalumabApproved